Last reviewed · How we verify
NCT03780712: RECIPAL
Immune Dysfunction in Newborn Sepsis
trial testing Non applicable in Sepsis Newborn in 585 participants. Completed in 12 March 2018.
12 March 2018
Quick facts
| Lead sponsor | BioMérieux |
|---|---|
| Status | Completed |
| Study type | OBSERVATIONAL |
| Enrollment | 585 |
| Start date | 17 April 2016 |
| Primary completion | 12 March 2018 |
| Estimated completion | 12 March 2018 |
Drugs / interventions tested
- Non applicable — full drug profile →
Conditions studied
- Sepsis Newborn — all drugs for Sepsis Newborn →
- Malaria — all drugs for Malaria →
- Immune Responses — all drugs for Immune Responses →
Sponsor
BioMérieux — full company profile →
Who can join
Eligibility, any sex, with Sepsis Newborn or Malaria. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
The aim of the project is to study neonatal immune dysfunction associated to the risk of newborn sepsis in a malaria endemic area in Benin.
Publications & conference data
3 peer-reviewed publications reference this trial (live from Europe PMC):
-
SEPSIS project: a protocol for studying biomarkers of neonatal sepsis and immune responses of infants in a malaria-endemic region.
Fievet N, Ezinmegnon S, Agbota G, Sossou D, et al · · 2020 · cited 6× · PMID 32709653 · DOI 10.1136/bmjopen-2020-036905 -
Prospective multicentre study of host response signatures in neonatal sepsis in Sub Saharan Africa.
Ezinmegnon S, Mommert M, Bartolo F, Agbota G, et al · · 2022 · cited 3× · PMID 36509812 · DOI 10.1038/s41598-022-25892-x -
Host Immunity Biomarkers of Neonatal Sepsis: A Prospective, Multicentre Study in Sub Saharan Africa
Ezinmegnon S, Mommert M, Bartolo F, Agbota G, et al · · 2021 · DOI 10.21203/rs.3.rs-561585/v2
Verify or expand the search:
- PubMed search for NCT03780712
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other trials of Non applicable
Trials testing the same drug.
- NCT07274631 — A Cohort for Inflammatory Respiratory Diseases: From Phenotyping to Personalised Medicine · recruiting
- NCT06449066 — Primary Immunodeficiencies and Obstetrical Neuraxial Anaesthesia · completed
- NCT06517290 — Evaluation of the Risk of Infection During Fever in Labor · completed
- NCT05465187 — Withholding or Withdrawing of Life-sustaining Therapy in Great East French Region Intensive Care Units: a 1-month Survey · completed
- NCT05407298 — The Use of Cannabidiol in Cancer Patients · completed
Other BioMérieux trials
Trials by the same sponsor.
- NCT06449183 — VIDAS® TBI Real Life Performance in Subjects With Mild Traumatic Brain Injury (mTBI) · NA · completed
- NCT06037109 — VIDAS® NEPHROCLEAR Reference Interval Study · completed
- NCT06036758 — VIDAS® NEPHROCLEAR Diagnostic Accuracy Study · completed
- NCT06257810 — Impact of Differential and Systematic Diagnosis of Dengue, Chikungunya and Malaria on Patient Management and Antibiotic · NA · completed
- NCT05271617 — VIDAS Nephroclear (NCL) CCL14 - Sample Stability · completed
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT03780712 (US National Library of Medicine, public domain)
- Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by BioMérieux
- Last refreshed: 19 December 2018
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03780712.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing